Multiple myeloma (MM) is a highly heterogenous disease that exists along a continuous
disease spectrum starting with premalignant conditions monoclonal gammopathy of …

Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that
are already known for use treating other diseases. The advantages of this are that several …

Over the past two decades, the natural history of multiple myeloma (MM) has evolved
dramatically, owing primarily to novel agents targeting MM in the bone marrow …

Abstract Human sideroflexin 2 (SFXN2) belongs to the SFXN protein family, which is a
mitochondrial outer membrane protein involved in mitochondrial iron metabolism …

Proteostasis, also known as protein homeostasis, is critical for cell survival. Autophagy is a
cellular process that degrades and recycles damaged or long-lived proteins, misfolded …

Multiple myeloma (MM) is a type of hematological cancer that occurs when B cells become
malignant. Various drugs such as proteasome inhibitors, immunomodulators, and …

Multiple myeloma is a type of malignant neoplasia whose treatment has changed over the
past decade. This study aimed to investigate the effects of combination of Adenovector …

Multiple myeloma (MM) is the prototypic cancer model for proteotoxicity due to the extensive
and sustained synthesis of immunoglobulin or free light chain in the face of insufficient …

Multiple myeloma (MM) is a malignant disease of the plasma cells representing
approximately 10% of all hemato-oncological diseases. Detection of the disease is most …

While the modern therapeutic armamentarium to treat multiple myeloma (MM) patients
allows a longer control of the disease, this second-most-frequent hematologic cancer is still …